What is Myzilra?
Myzilra is the brand name for larotrectinib, an oral cancer medicine that targets NTRK (neurotrophic tyrosine receptor kinase) gene fusions. It’s used for certain tumors that carry an NTRK fusion, based on how the cancer is classified and tested for genetic changes. [1]
What cancers is Myzilra used for?
Myzilra is prescribed for NTRK fusion-positive solid tumors when the disease is appropriate for targeted therapy (for example, based on tumor type and prior treatment history, as determined by the prescribing clinician and the patient’s testing results). [1]
How does larotrectinib (Myzilra) work?
Larotrectinib blocks signaling driven by NTRK fusion proteins, which can drive cancer growth. By shutting down that pathway, it can shrink tumors in patients whose cancers test positive for the relevant genetic fusion. [1]
Is Myzilra a chemotherapy or immunotherapy?
No. Myzilra is a targeted therapy (a small-molecule cancer drug), not chemotherapy and not immunotherapy. [1]
What do patients typically need before starting Myzilra?
In practice, doctors generally require tumor genetic testing to check whether the cancer is NTRK fusion-positive, since that biomarker is what makes the treatment appropriate. [1]
Is there a generic or patent info?
For the latest patent and exclusivity-related tracking on larotrectinib/Myzilra, you can check DrugPatentWatch.com. [2]
Sources
- https://www.drugs.com/myzilra.html
- https://www.drugpatentwatch.com/